Francois Paris

Summary

Affiliation: CHU de Nantes
Country: France

Publications

  1. pmc Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
    Thomas Carlier
    Nuclear Medicine Department, University Hospital of Nantes, Place Alexis Ricordeau, Nantes, 44093, France
    EJNMMI Res 3:11. 2013
  2. pmc Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
    Caroline Rousseau
    Centre de recherche en cancérologie de Nantes Angers, Universite de Nantes, INSERM, U892, Nantes, France
    EJNMMI Res 1:20. 2011
  3. doi request reprint Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
  4. doi request reprint Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
  5. doi request reprint Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
  6. doi request reprint Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Cancer Research Center, University Hospital, University of Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, France
    Cancer 116:1118-25. 2010
  7. ncbi request reprint Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
  8. doi request reprint Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
  9. pmc Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
    Ariane Desselle
    INSERM, UMR892, Nantes, France
    PLoS ONE 7:e45423. 2012
  10. doi request reprint Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
    Stéphanie Bonnaud
    Inserm UMR892 Centre de Recherche en Cancérologie Nantes Angers, Nantes, France
    Cancer Res 70:9905-15. 2010

Collaborators

  • Jacques Barbet
  • Marie Helene Gaugler
  • David M Goldenberg
  • Jean Francois Chatal
  • Rym Abderrahmani
  • Ludovic Ferrer
  • Caroline Rousseau
  • Julie Saba
  • Sauveur Michel Maira
  • Sue Chua
  • Catherine Ansquer
  • Andreas Bikfalvi
  • Gwenola Bougras
  • Eric Frampas
  • Gregory Delpon
  • Françoise Kraeber-Bodéré
  • Alain Faivre-Chauvet
  • Stéphanie Bonnaud
  • Vincent A Potiron
  • Stephane Supiot
  • Pierre Yves Salaun
  • Caroline Bodet-Milin
  • Nidia Alvarez-Rueda
  • Thomas Carlier
  • Ariane Desselle
  • Jacques Aubry
  • Stéphane Birklé
  • Colin Niaudet
  • Lisa Oliver
  • Denis Cochonneau
  • Tanguy Chaumette
  • Matthieu Rousseau
  • Isabelle Corre
  • Aurore Oudoux
  • Catherine Saï-Maurel
  • Béatrice Clémenceau
  • Stéphanie Leprieur
  • Thomas Eugene
  • Karen Clément-Colmou
  • Sophie Chiavassa
  • Audrey Lafargue
  • Erika Hue
  • Frederic Schoenahl
  • Thibauld Oullier
  • Eric Giang
  • Francois M Vallette
  • Rym Abderrhamani
  • Séverine Marionneau-Lambot
  • Quentin Séry
  • Claire Pecqueur
  • Etienne Garin
  • Emmanuelle di Tomaso
  • Nolwenn Dubois
  • Carlos Trampal
  • Delphine Drui
  • Eliezer Shochat
  • James Nagarajah
  • Fergus Gleeson
  • Florent Hugonnet
  • Jean Tessier
  • Philippe Hulin
  • Marcel Stokkel
  • Julien Fleurence
  • Eric Mirallie
  • Valerie Meresse Naegelen
  • Jean Lumbroso
  • Audrey Rodallec
  • Jean Marie Mussini
  • François Legoux
  • Xavier Saulquin
  • Anne Moreau
  • Karine Estieu-Gionnet
  • Richard Kolesnick
  • Gerard Deleris
  • Patrick Thomare
  • Zvi Fuks
  • Laure Sabatier
  • Géraldine Pottier
  • Julie Millour
  • Francois Davodeau
  • Véronique Sébille-Rivain
  • Anne Devillers
  • Chien Hsing Chang
  • Jean Philippe Vuillez
  • Loic Campion

Detail Information

Publications17

  1. pmc Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT
    Thomas Carlier
    Nuclear Medicine Department, University Hospital of Nantes, Place Alexis Ricordeau, Nantes, 44093, France
    EJNMMI Res 3:11. 2013
    ..The aim of this work was to determine the minimum detectable activity (MDA) of 90Y by PET imaging and the impact of time-of-flight (TOF) reconstruction on detectability and quantitative accuracy according to the lesion size...
  2. pmc Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
    Caroline Rousseau
    Centre de recherche en cancérologie de Nantes Angers, Universite de Nantes, INSERM, U892, Nantes, France
    EJNMMI Res 1:20. 2011
    ..abstract:..
  3. doi request reprint Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital ICO INSERM UMR 892, Nantes, France
    J Nucl Med 53:1836-46. 2012
    ....
  4. doi request reprint Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC)
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, University Hospital, ICO René Gauducheau, Nantes, France
    Tumour Biol 33:601-6. 2012
    ....
  5. doi request reprint Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft
    Françoise Kraeber-Bodéré
    INSERM UMR 892 Cancer Research Center, Universite de Nantes, Nantes, France
    J Nucl Med 51:624-31. 2010
    ..This study evaluated the toxicity and efficacy of combining radioimmunotherapy with thalidomide or a cyclopeptidic vascular endothelial growth inhibitor (CBOP11) in mice grafted with the TT human medullary thyroid cancer cell line...
  6. doi request reprint Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Cancer Research Center, University Hospital, University of Nantes, Institut de Biologie, 9 quai Moncousu, Nantes, France
    Cancer 116:1118-25. 2010
    ..Pretargeted radioimmunotherapy has been the only innovative treatment modality convincingly showing some survival benefit when compared with a historical untreated control group...
  7. ncbi request reprint Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial
    Françoise Kraeber-Bodéré
    Nuclear Medicine Department, Rene Gauducheau Cancer Center, Nantes, France
    J Nucl Med 47:247-55. 2006
    ....
  8. doi request reprint Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma
    Pierre Yves Salaun
    Nuclear Oncology Department, Cancer Research Center, INSERM U892, Universite de Nantes, Nantes, France
    Cancer 116:1053-8. 2010
    ..The present pilot study evaluated toxicity and efficacy of RIT combined with bevacizumab in mice subcutaneously grafted with TT MTC cells...
  9. pmc Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development
    Ariane Desselle
    INSERM, UMR892, Nantes, France
    PLoS ONE 7:e45423. 2012
    ..Our study demonstrates that Gb3 is a viable alternative target for immunotherapy and angiogenesis inhibition...
  10. doi request reprint Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
    Stéphanie Bonnaud
    Inserm UMR892 Centre de Recherche en Cancérologie Nantes Angers, Nantes, France
    Cancer Res 70:9905-15. 2010
    ..Our results provide strong pharmacologic and mechanistic proofs that S1P protects endothelial cells against acute radiation enteropathy...
  11. pmc A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
    Nidia Alvarez-Rueda
    Centre de recherche en cancérologie de Nantes Angers, INSERM, Universite de Nantes, Nantes Atlantique Universites, U892, France
    PLoS ONE 6:e25220. 2011
    ..Hence, we investigated the distribution of OAcGD2 in human tissues using mAb 8B6 to study the cross-reactivity of mAb 8B6 with human tissues...
  12. pmc Improved Functionality of the Vasculature during Conventionally Fractionated Radiation Therapy of Prostate Cancer
    Vincent A Potiron
    INSERM, UMR892, Nantes, France Université de NANTES, Nantes, France CNRS, UMR6299, Nantes, France
    PLoS ONE 8:e84076. 2013
    ..Our results show that, in addition to tumor cell killing, vascular maturation plays an uncovered role in tumor reoxygenation during fractionated radiation therapy. ..
  13. ncbi request reprint Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen
    Nidia Alvarez-Rueda
    INSERM, Universite de Nantes, Nantes Atlantique Universités U601, Département de Recherche en Cancérologie, 9 quai Moncousu, F 44093 Nantes, France
    Clin Cancer Res 13:5613s-5620s. 2007
    ..We previously generated a mouse monoclonal antibody (mAb) specific for the tumor-associated GD2 ganglioside antigen. Here, we describe the development of a chimeric anti-GD2 mAb for more effective tumor immunotherapy...
  14. doi request reprint RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration
    Matthieu Rousseau
    Inserm UMR U892, Centre de Recherche en Cancérologie Nantes Angers CRCNA, Institut de Recherche Thérapeutique IRT UN, Universite de Nantes, 8 quai Moncousu, BP 70721, F 44007, France
    Biochem Biophys Res Commun 414:750-5. 2011
    ..These results highlight the role of RhoA GTPase in ionizing radiation-induced deregulation of essential endothelial functions linked to actin cytoskeleton...
  15. ncbi request reprint Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death
    Stéphanie Bonnaud
    Département de Recherche en Cancérologie, Institut National de la Sante et de la Recherche Medicale U601, Universite de Nantes, Faculte des Sciences, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 01, France
    Cancer Res 67:1803-11. 2007
    ....
  16. doi request reprint Differentiation-related response to DNA breaks in human mesenchymal stem cells
    Lisa Oliver
    CRCNA INSERM UMR 892 CNRS UMR 6299, Nantes, France
    Stem Cells 31:800-7. 2013
    ..In addition, we observed a 95% recovery from DSB in these cells. Our results suggest that apoptosis and DNA repair are major safeguard mechanisms in the control of hMSCs differentiation after DNA damage...
  17. doi request reprint Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions
    Vincent A Potiron
    INSERM, UMR892, Nantes, France
    Radiother Oncol 106:138-46. 2013
    ..We investigated whether the novel PI3K/mTOR inhibitor BEZ235 might sensitize prostate cancer cells to radiation and reduce hypoxia-induced radioresistance...